Researchers from the National Institutes of Health (NIH) and Memorial Sloan Kettering Cancer Center (MSKCC) have unveiled an innovative AI model that predicts responses to immunotherapy. This model, called LORIS, integrates various clinical factors like age, cancer type, prior treatments, blood albumin levels, and neutrophil-to-lymphocyte ratio. By incorporating DNA sequencing data and tumor mutational burden, the AI accurately identifies patients likely to respond positively to immune checkpoint inhibitors. This breakthrough offers insights into both short and long-term survival outcomes across different cancer types. #Immunotherapy #AIModel
Caizio’s Post
More Relevant Posts
-
The National Institutes of Health scientists have developed an AI tool to predict cancer patients' responses to immunotherapy. 🧬 This innovative ML model uses routine clinical data to help #doctors determine the effectiveness of immune checkpoint inhibitors. 🩺 Key features include age, cancer type, blood markers, and tumor mutational burden. The study, published in Nature #Cancer, promises a leap forward in personalized cancer treatment. 📈 🔗Read More - https://lnkd.in/dZ7NKUzE 🖊️Writes - Nikita Saha #CancerResearch #AI #Immunotherapy #NIH #HealthcareInnovation #MedicalScience #CancerTreatment #FutureOfMedicine
NIH Scientists Develop AI Tool to Predict How Cancer Patients will Respond to Immunotherapy
digitalhealthnews.com
To view or add a comment, sign in
-
🌟 **Harnessing the Power of Precision Cancer Therapy** 🌟 The future of cancer treatment lies in precision medicine, where therapies are tailored to the individual genetic profiles of patients. Precision cancer therapy offers a personalized approach, targeting specific genetic mutations and molecular markers within tumors. This innovative method is transforming oncology, providing more effective and less toxic treatments. (https://lnkd.in/e3rUvR2M). The era of one-size-fits-all cancer treatment is fading. Embracing precision medicine means embracing a future where cancer care is as unique as the patients we treat. By analyzing the genetic mutations within a patient's tumor, NGS helps identify targeted therapies that are more effective and less toxic than traditional therapis. 🔬 *Key Benefits of NGS in Cancer Therapy:* 1. *Personalized Treatment Plans*: Tailoring therapies based on individual genetic profiles. 2. *Early Detection*: Identifying genetic mutations that can lead to cancer before it progresses. 3. *Improved Outcomes*: Enhancing the effectiveness of treatments and reducing side effects. 4. *Ongoing Monitoring*: Tracking the evolution of cancer to adjust treatments as needed. 🌍 *Impact on Patient Care*: NGS is paving the way for a new era in oncology, where treatments are customized to each patient's unique genetic makeup, leading to better outcomes and quality of life. The future of cancer therapy is here, and it's powered by the precision of NGS. Let's embrace this innovative approach to make a real difference in the lives of cancer patients. #NextGenerationSequencing #CancerTherapy #PrecisionMedicine #Precisiononcology
To view or add a comment, sign in
-
A Medical Device Network article discusses DELFI Diagnostics's new test, claiming: "With a negative predictive value of 99.8%, the test is highly reliable, potentially missing only two in one thousand cases of lung cancer." https://lnkd.in/drJbG-KS Negative predictive value (NPV) is not exactly this. NPV is the ratio of false negative results to all the negative results. 1 - NPV represents your chance of being sick despite having a negative test result. (NPV results always seem to be very impressive.) In the same article, Johns Hopkins Cancer Genetics and Epigenetics programme co-director Victor Velculescu said: “We have a simple blood test that could be done in a doctor’s office that would tell patients whether they have potential signs of lung cancer and should get a follow-up CT scan.” Well, it would be amazing to have such a method: a point-of-care fragmentomics test. #CancerScreening #15
Johns Hopkins announces new blood test for early lung cancer detection
medicaldevice-network.com
To view or add a comment, sign in
-
This guide from Memorial Sloan Kettering is an essential resource for anyone diagnosed with lung cancer, underscoring the importance of an individualised, informed approach to treatment. Dr. Mark Awad’s emphasis on the need for specialised genomic testing and personalised care reflects the latest advancements in oncology, where treatments are now increasingly tailored to specific genetic mutations—such as EGFR, KRAS, and ALK—that influence therapeutic response. Inquiring about biomarker testing, treatment staging, and team expertise is crucial, as this information directly impacts the choice of therapies, from immunotherapies to targeted drugs, which are often key to improved outcomes. These steps ensure that patients are not only equipped with knowledge but are also in a position to make decisions that align with their life goals and quality-of-life expectations throughout treatment. #lungscreen #cancer #diagnosis
Questions to Ask If You've Been Diagnosed With Lung Cancer
mskcc.org
To view or add a comment, sign in
-
We’re thrilled to share groundbreaking results from SpotitEarly's Rainbow Study, recently published in Scientific Reports. This study showcases our revolutionary breath-based cancer screening test, which leverages a bio-AI hybrid platform combining the unparalleled detection abilities of trained canines with cutting-edge artificial intelligence. Our approach is non-invasive, requiring only a simple breath sample, and demonstrated exceptional accuracy across multiple cancer types. The numbers speak for themselves: • 93.9% sensitivity and 94.3% specificity across breast, lung, prostate, and colorectal cancers • 95% sensitivity for early-stage (0-2) cancer detection • Over 1,400 participants aged 22-94 Curious to learn more? Check out the full press release attached to this post including a link to the paper. #CancerDetection, #EarlyDetection, #AIInHealthcare, #CancerScreening, #BioAI, #MedicalBreakthrough, #HealthTech https://lnkd.in/g2SmVnG6
New Study Indicates SpotitEarly Detects Multiple Cancers Early By Using AI, Trained Canines And Breath Samples
prnewswire.com
To view or add a comment, sign in
-
🚀 Exciting News from SpotitEarly! A recent study shows that our technology can detect multiple types of cancers with remarkable accuracy. This breakthrough is a huge step forward in our mission to harness the power of Nature & AI for early cancer detection. 🔍 Dive deeper into the details of this pivotal study and what it means for the future of health care.
We’re thrilled to share groundbreaking results from SpotitEarly's Rainbow Study, recently published in Scientific Reports. This study showcases our revolutionary breath-based cancer screening test, which leverages a bio-AI hybrid platform combining the unparalleled detection abilities of trained canines with cutting-edge artificial intelligence. Our approach is non-invasive, requiring only a simple breath sample, and demonstrated exceptional accuracy across multiple cancer types. The numbers speak for themselves: • 93.9% sensitivity and 94.3% specificity across breast, lung, prostate, and colorectal cancers • 95% sensitivity for early-stage (0-2) cancer detection • Over 1,400 participants aged 22-94 Curious to learn more? Check out the full press release attached to this post including a link to the paper. #CancerDetection, #EarlyDetection, #AIInHealthcare, #CancerScreening, #BioAI, #MedicalBreakthrough, #HealthTech https://lnkd.in/g2SmVnG6
New Study Indicates SpotitEarly Detects Multiple Cancers Early By Using AI, Trained Canines And Breath Samples
prnewswire.com
To view or add a comment, sign in
-
🚨 Exciting News from SpotitEarly! 🚨 Our Rainbow Study, now published in Scientific Reports, highlights our revolutionary breath-based cancer screening test. Using trained canines and AI, we’ve achieved a non-invasive, accurate solution for early cancer detection. 🔍 Key Results: ➡️ 93.9% sensitivity and 94.3% specificity across four cancers. ➡️ 95% sensitivity for early-stage (0-2) cancers. ➡️ Over 1,400 participants aged 22-94. This is a game-changer for early cancer detection! 👉 Read more here: https://lnkd.in/g2SmVnG6 #EarlyDetection #CancerScreening #BioAI #HealthTech
We’re thrilled to share groundbreaking results from SpotitEarly's Rainbow Study, recently published in Scientific Reports. This study showcases our revolutionary breath-based cancer screening test, which leverages a bio-AI hybrid platform combining the unparalleled detection abilities of trained canines with cutting-edge artificial intelligence. Our approach is non-invasive, requiring only a simple breath sample, and demonstrated exceptional accuracy across multiple cancer types. The numbers speak for themselves: • 93.9% sensitivity and 94.3% specificity across breast, lung, prostate, and colorectal cancers • 95% sensitivity for early-stage (0-2) cancer detection • Over 1,400 participants aged 22-94 Curious to learn more? Check out the full press release attached to this post including a link to the paper. #CancerDetection, #EarlyDetection, #AIInHealthcare, #CancerScreening, #BioAI, #MedicalBreakthrough, #HealthTech https://lnkd.in/g2SmVnG6
New Study Indicates SpotitEarly Detects Multiple Cancers Early By Using AI, Trained Canines And Breath Samples
prnewswire.com
To view or add a comment, sign in
-
Imagine your mother, sister, friend, neighbor, or colleague being diagnosed with a disease where the odds of being cured are equivalent to that of a coin toss. That's the reality of #ovariancancer, which has a 5-year survival rate of just 50.8%. Luckily, researchers are starting to uncover vital clues in the immune landscape of cancer tissues that may offer hope for more effective therapeutic strategies. 📚 Read about how scientists at Cedars-Sinai Medical Center in Los Angeles, CA, led by Michelle Jones, Ph.D, are using advanced #spatialproteomics analysis to dive deeper into the tumor microenvironment of high-grade serous ovarian cancer (#HGSOC): https://bit.ly/4aq6waJ 📺 Watch this great short video of Kruttika Dabke (now of the Ellison Institute of Technology Los Angeles) explaining the findings: https://bit.ly/4a8vATh It's a great way to mark World Ovarian Cancer Day! #NoWomanLeftBehind #WOCD2024 #WorldOvarianCancerDay #oncology #TME
Unraveling how DNA repair mutations drive cellular changes in ovarian cancer to improve patient outcomes
https://www.akoyabio.com
To view or add a comment, sign in
-
🔬 Exciting News in Cancer Diagnosis: BioGenex Introduces Anti-VISTA Antibody for Enhanced Lung Tumor Detection! We are thrilled to announce the latest innovation from BioGenex: the Anti-VISTA antibody designed for precise diagnosis of lung tumors. VISTA (V-domain immunoglobulin suppressor of T cell activation) is a critical immune checkpoint protein predominantly found on tumor cells. Its role in suppressing T cell activity makes it a significant target for cancer diagnostics and treatment. Key Features: 🌟 Targets VISTA, an inhibitory protein expressed on tumor cells 🔬 Suppresses T cell function, impacting tumor growth and immune response 🎯 Highly expressed in non-small cell lung cancer and other major cancers BioGenex offers ready-to-use (RTU) and concentrated formats suitable for both manual and automated systems. These products are designed to empower pathologists and clinicians with precise diagnostic tools, enhancing clinicopathological assessments and advancing drug discovery efforts. Stay ahead in cancer diagnostics with BioGenex’s cutting-edge solutions. Learn more about how our Anti-VISTA antibody can optimize your diagnostic protocols and improve patient outcomes. Learn More: https://hubs.la/Q02DBBHj0 #BioGenex #CancerResearch #LungCancer #AntiVISTA #Immunotherapy #MedicalInnovation #Pathology #PrecisionMedicine
To view or add a comment, sign in
-
-
"Cancer." It's a 6-letter word that carries a universal understanding of a condition affecting nearly 20 million people worldwide each year. The simplicity of the term, however, disguises an incredibly complex and varied disease process unfolding at the cellular level. #Cancer is no one thing, but rather a vast umbrella of diseases triggered by the out-of-control proliferation of rogue cells. Individual cells, tumors, patients, and types of cancer each bring a new layer of idiosyncrasy. How can we create biologically relevant models of a disease with so many variables? A newly standardized, off-the-shelf #tumoroid medium culture kit is poised to change the game for cancer researchers – enabling a 3D view into the tumor microenvironment and patient-derived tumor cells. 🆕 Read our NEW story to learn why Gibco OncoPro Tumoroid Medium Culture Kit is one of this year's contenders for SelectScience®'s Scientist' Choice Awards for new products with the biggest potential impact on research and lab work in 2023 and beyond. Read now:
Cancer Research in 3D with Tumoroid Culture Medium
thermofisher.com
To view or add a comment, sign in